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Enoxaparin displays fibrinolytic activity through stimulation of endothelial release of tissue plasminogen activator.
Moreover, enoxaparin increases the release of tissue factor pathway inhibitor, which inhibits coagulation activity.
However, there are only few reports regarding the use of enoxaparin for the treatment of children with thrombosis
complicating congenital heart disease. We report the clinical findings from two patients, one child with an A.
cerebri media infarction and another with a left ventricular thrombus. In both cases successful thrombolysis was
obtained by intravenous administration of enoxaparin. The first patient was a 12-year-old girl with an atrioventricular
septal defect, who underwent biventricular repair at the age of 8 months. She presented with right-sided middle
cerebral artery infarction. Thrombolysis was contraindicated, because she was beyond the therapeutic window
recommended by accepted guidelines. Enoxaparin 2.5 mg/kg/d was administered as a continuous intravenous
infusion (CII). The MRI 10 days later revealed a reopened middle cerebral artery and she experienced complete
remission of the neurological signs. The second patient was a 16-year-old boy who had tetralogy of Fallot corrected
in late infancy. He presented with severe heart failure and a mural thrombus in the left ventricular apex. Enoxaparin
was administered and resulted in complete disappearance of the thrombus within a week. According to our
experience, CII of enoxaparin was safe and well tolerated without secondary bleeding and resulted in complete
dissolution of the thrombi without secondary embolization. Therefore, CII of enoxaparin may be a possible
alternative for the treatment of thrombotic complications in children with contraindications against conventional
thrombolytic therapy.
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In the pediatric population, the treatment of venous
thromboembolism (VTE) is hampered by a lack of ad-
equate pediatric guidelines or large-scale pediatric studies.
Until recent years, the administration of unfractioned
heparin (UFH) followed by an oral anticoagulant was
regarded as the therapy of choice for the treatment of
VTE in children. However, low-molecular-weight hep-
arin (LMWH), especially enoxaparin, since the early
nineties is increasingly used in the pediatric population* Correspondence: gesa.wiegand@med.uni-tuebingen.de
1Department of Pediatric Cardiology, University Children’s Hospital,
Hoppe-Seyler-Strasse 1, 72076 Tuebingen, Germany
Full list of author information is available at the end of the article
© 2014 Wiegand et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.[1-5] and is recommended by the guidelines of the
American College of Chest Physicians [6]. Nevertheless it
is necessary to mention, that neither the subcutaneous nor
the intravenous application of enoxaparin is approved for
use in children. Therefore written informed consent of the
parents is recommended prior to application.
Enoxaparin has a fibrinolytic activity through stimulation
of endothelial release of tPA (tissue plasminogen activator)
[7]. Moreover, enoxaparin increases tissue factor pathway
inhibitor (TFPI) release, which inhibits coagulation activity
[8]. However, only few reports describe the use of enoxa-
parin via continuous intravenous infusion (CII) [9-11]. As
substantial variability of the plasmatic anti-Xa concentra-
tions were being observed during standard subcutaneousal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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introduced the CII route to increase the efficiency of the
therapy. Therefore, they evaluated the pharmacokinetic
profile and defined a dosage strategy for administering
enoxaparin by CII even in patients with altered renal func-
tion [9]. Kane-Gill et al. also reported about administration
of enoxaprin as CII to evaluate the influence of renal func-
tion on enoxaparin activity [10]. Lorenzini et al. mentioned
two patients who received the drug by CII while being on
renal replacement therapy (hemofiltration) for 15 and
60 days [11].
So far, however we identified no mention in the litera-
ture of this therapy for the treatment of children with
thrombosis complicating congenital heart disease.
Case presentation
The first patient (patient 1) was a 12-year-old girl with a
complex congenital cardiac malformation (heterotaxy
syndrome including atrioventricular septal defect and
partial anomalous pulmonary venous return), who
underwent biventricular repair at the age of 8 months.
At the age of 12 years, the girl presented with left-sided
hemiparesis. Magnetic resonance imaging (MRI) re-
vealed a right-sided middle cerebral artery infarction
(Figure 1a) with infarct demarcation in the right hemi-
spheric white matter. Conventional thrombolysis with
rtPA was contraindicated because she presented more
than 6 hours after symptoms commenced, which was
beyond the therapeutic window recommended for the
adult population according to accepted guidelines [12].
Transoesophageal echocardiography was unremarkable
with no intracardiac thrombus formations.
Enoxaparin (2.5 mg/kg/d) was administered by CII (anti-
Xa levels 0.6–1.0 IU/ml). Hereby we calculated the dosage
of enoxaparin according to the guidelines of the American
College of Chest Physicians [6] with age specific dosages of
1–1.5 mg twice daily, respectively 2–3 mg/kg/d. We usedFigures 1 Cerebral arteriogram showing a right-sided middle cerebra
enoxaparin, the MRI revealed normal perfusion of the cerebral arteries (b).enoxaparin sodium as pre-filled syringes, which was diluted
in 50 ml saline 0.9% and was changed every 24 hours, since
the physical and chemical stability was verified for periods
longer than 24 h at a temperature of 21°C [13]. Within
a few days the girl experienced complete remission of
the clinical symptoms and 10 days later the MRI revealed a
patent middle cerebral artery (Figure 1b). After 4 days,
enoxaparin was switched from CII to a subcutaneous ad-
ministration with anti-Xa levels still kept above 0.6 - 1 IU/
ml. The switch of the administration route was decided in
view of the disappearance of the clinically relevant hemipar-
esis and a normal transcranial doppler profile. D-dimer
levels (normal range: 0–0.23 μg/ml) were not elevated dur-
ing therapy with a maximum of 0.06 μg/ml measured on
the first day.
The second patient was a 16-year-old boy (patient 2)
who had tetralogy of Fallot corrected in late infancy. The
patient reported progressive fatigue for one month and
recurrent episodes of stomach ache. Echocardiography
revealed severe heart failure with an enlarged and poorly
contracting left ventricle, a moderate mitral valve insuffi-
ciency and a mural thrombus formation in the left ven-
tricular apex (Figure 2a). Enoxaparin was administered
at 2 mg/kg/d as a CII, in addition to inotropic medication
with dobutamine and levosimendan, amongst others. Due
to a modest elevation of anti-Xa levels, enoxaparin was in-
creased to 4 mg/kg/d for a few hours. The thrombus di-
minished in size and complete dissolution occurred within
one week (Figure 2b). During this therapy there was no
evidence for thrombus embolization and a cranial CT scan
discovered no evidence of intracranial hemorrhage. A
chest CT scan confirmed the diagnosis of cardiomegaly
and hypodense structures in the apex of the left ventricle
correlated with thrombus formation. After 7 days the CII
was switched to a subcutaneous administration with simi-
lar anti-Xa levels and after 2 weeks the antithrombotic
therapy was switched to acetylsalicylic acid because ofl artery infarction (a). Following thrombolytic therapy with
Figures 2 Echocardiography of the left ventricle shows thrombus formation in the apex (a). Following thrombolytic therapy with
enoxaparin, echocardiography revealed complete disappearance of the thrombus (b).
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During enoxaparin treatment, d-dimer levels increased to
a maximum of 5.1 μg/ml after 2 days of therapy.
Cardiac catheterization including myocardial biopsy was
performed and showed that the etiology of the severe
heart failure was dilative cardiomyopathy of unknown ori-
gin. The CII of enoxaparin was paused 4 hours prior to
the invasive procedure.
To obtain a more efficient thrombolysis, anti-Xa levels
were raised to the upper limits of the recommended
therapeutic levels (between 0.7 and 1.0 IU/ml [7]).
Platelet counts were monitored daily. None of the pa-
tients had renal dysfunction or manifested signs of hep-
arin induced thrombycytopenia (HIT).
Routine thrombophilia screening, including APC resist-
ance, factor II mutation, protein C and S, antithrombin,
homocysteine, lipoprotein (a), antiphospholipid antibodies
and factor VIII, was negative in both patients prior to the
enoxaparin therapy.
Discussion
LMWHs are prescribed for the treatment and preven-
tion of several conditions including deep venous throm-
bosis, pulmonary embolism, acute coronary syndromes
and atrial fibrillation [10,14,15]. The standardized
method of administration for LMWH, including enoxa-
parin, is by subcutaneous injection, but Kane-Gill et al.
found that the safety of enoxaparin administered by CII
was comparable to that of subcutaneous administration
[10]. Intravenous application has also been described in
patients during percutaneous coronary interventions
[16]. Few reports exist on the use of LMWHs by CII in
the setting of deep vein thrombosis, hemodialysis and
pulmonary embolism [11,17], and there is even less in-
formation regarding the use of LMWH administered as
a CII in children [18]. In both of our patients, we started
with an initial dosage of 2–2.5 mg/kg as a CII. Despite
being aware of the fact that the peak drug level is
reached 4 hours following subcutaneous administration,
we undertook a first sampling of the anti-Xa levels 6–8hours after the start of the infusion. We chose to wait
that long in order to obtain a steady-state, especially in
view of the fact that despite administering the same
dosage over several days in the setting of CII the anti-
Xa levels seemed to increase further. Therefore, daily
blood sampling was performed because anti-Xa levels -
as we expected - continued to rise, especially during the
first two to three days. In both patients, a therapeutic
level of 0.6–1.0 IU/ml was obtained with a dosage of
1.8–2.5 mg/kg/d (Figure 3a and b). Administration of
enoxaparin for “thrombolysis” via CII can result in a
more constant and predictable anticoagulation than
subcutaneous injection [10].
During the treatment, d-dimer levels of the patient 2
increased to a maximum of 5.1 μg/ml after 2 days of
therapy. In combination with a thrombus regression
seen on echocardiography, we consider this as a sign of
thrombus regression by thrombolysis.
Enoxaparin has a predominantly renal clearance [19].
Renal dysfunction was suggested to be involved in ele-
vated anti-Xa levels, and subsequently in bleeding com-
plications [9]. This association was not confirmed by
others [10]. Anti-Xa clearance in ICU patients is about
half of their non-ICU counterparts, caused by altered
enoxaparin pharmacokinetics in the critically ill [10,20].
Therefore, in the initial phase of the therapy anti-Xa
levels should be monitored daily, and, according to the
manufacturer, dose reduction applied for creatinine clear-
ance values of below 30 ml/min.
In the literature, reported undesirable side effects caused
by CII of enoxaparin include gastrointestinal bleeding, epi-
staxis, bleeding from the oral mucosa, thrombocytopenia
and wound bleeding, none of which correlate with high
anti-Xa levels [10]. In our two patients, however, there
were no adverse reactions.
When compared to other established LMWH drugs,
enoxaparin shows the highest anti-Xa activity, the high-
est anti-thrombin effect and the longest biological halflife
[8]. Antithrombotic effects are the result of inhibition of
the tissue factor/factor VIIa complex and the release of
Figures 3 Anti-Xa levels of patient 1 (a) and patient 2 (b) in correlation with the administered enoxaparin (Clexane) dosage.
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ities such as the ability to significantly increase tPA release
from endothelial cells [7,8].
According to our experience, intravenous adminis-
tration of enoxaparin as a CII appears to be safe and
well tolerated without bleeding complications. In both
patients, CII of enoxaparin resulted in complete dissol-
ution of the thrombi without secondary embolization.
Therefore, CII of enoxaparin may be a possible
alternative treatment for thrombotic complications in
children with contraindications against conventional
thrombolytic therapy.
Based on the data of our two patients, anti-Xa levels
were higher when the same therapeutic dosage of enoxa-
parin (2 mg/kg/d) was administered by CII than by sub-
cutaneous administration. Similar observations were
reported by Sanchez-Pena et al. who found that anti-Xa
activities were almost doubled when enoxaparin was ad-
ministered intravenously rather than subcutaneously
[16]. Additionally, in contrast to subcutaneous adminis-
tration, where anti-Xa levels reflect only the maximalpeak activity, CII of enoxaparin results in more stable
and predictable anti-Xa levels, which lead to more con-
sistent anticoagulant effects.
CII of enoxaparin is advantageous, particularly for chil-
dren who cannot be treated at home, because it avoids re-
peated painful injections, which may improve the patient’s
quality of living. Furthermore, CII also allows application
via a peripheral venous catheter. Another advantage is evi-
dent in children with very low weight, because it is often
difficult to give a small dose subcutaneously due to the
very small amount of medication injected [18].Conclusion
CII of enoxaparin is as safe as subcutaneous administra-
tion and can be safely used for both thrombolysis and
prophylaxis in hospitalized patients with a wide range of
thrombotic conditions.
Pharmacokinetic studies in the paediatric population
and further fine-tuning of the dosage regimens in chil-
dren will be evaluated in future.
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Written informed consent was obtained from the patients
for publication of both case reports and any accompany-
ing images. A copy of written consent is available for
review by Editor-in-Chief of this journal.
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